Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

9. Check if this filing amends a previously filed version of this report

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

Lobby members of Congress regarding issues related to telemedicine.
Advocate for a stable supply of medications and for mitigation of drug shortages, including lidocaine.
Advocate for increased transparency regarding drug pricing.
Advocate for reducing barriers to entry of generic drugs into the marketplace.
Advocate for transparency on the part of pharmaceutical benefit managers.
Advocate for patient access to compounded medications.
Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals and services.
Advocate for a stable supply of medications and mitigate drug shortages.
Lobby members of the House to join the Congressional Skin Cancer Caucus.
Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks.
Support H.R. 2630/S. 652, Safe Step Act.
Support S. 127, Pharmacy Benefit Manager Transparency Act
Advocate for relief from prior authorization requirements under Medicare Advantage and Medicare Part D plans.
Advocate for the continued and increased funding of Community Health Centers.
Advocate for implementation of surprise medical billing legislation (enacted as part of P.L. 116-260, Consolidated Appropriations Act, 2021, H.R. 133) as intended by Congress.

Support H.R. 1202/S. 704, Resident Education Deferred Interest Act or the REDI Act
Support the Resident Physician Shortage Reduction Act (S.1302/H.R. 2389)
Lobbied Congress on physician workforce, administrative burden, and workforce diversity issues
Advocate for the FDA to implement the 2015 rule, General and Plastic Surgery Devices: Restricted Sale, Distribution, and Use of Sunlamp Products; and the Sunlamp Products Proposed; Amendment to Performance Standard, which would ban minors under the age of 18 from using tanning beds.
Advocate for implementation of language to direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes (enacted as part of P.L. 117-328, Consolidated Appropriations Act, 2023, H.R. 2617).
Advocate to replace scheduled and anticipated cuts in Medicare payments with positive, inflationary-based updates, eliminate the anticipated conversion factor cut in the CMS proposed rule for the 2024 Medicare Physician Fee Schedule (MPFS) associated with budget neutrality adjustments tied to Evaluation & Management (E/M) Code MPFS policy changes
Advocate against H.R 618, Improving Access to Workers Compensation for Injured Federal Workers Act, which expands the role of nurse practitioners and physician assistants in providing services to injured federal workers under the federal workers' compensation program.
Lobbied Congress on impact of the burden of small business issues impacting small physician practices, including Medicare reimbursement cuts.
Advocate for H. Res. 365, in support of efforts to curb the incidences of skin cancer beginning with childhood skin protection.
Support H.R.2474, Strengthening Medicare for Patients and Providers Act.
Support H.R. 2761, S. 705, Specialty Physicians Advancing Rural Care Act (SPARC Act).
Support H.R. 4402, Protecting and Continuing Physician Education and Patient Care Act
Support H.R. 830/S. 1375, the Help Ensure Lower Patient (HELP) Copays Act.
Support H.R. 3674, the Providing Relief and Stability for Medicare Patients Act of 2023.
Support S. 935, the Fair Accountability & Innovative Research (FAIR) Drug Pricing Act.
Advocate regarding matters related to Merit-based Incentive Payment System (MIPS), MIPS Value Pathways (MVPs), and Qualified Clinical Data Registries.
Advocate regarding AADA efforts in skin cancer prevention and AADA skin cancer prevention programs and initiatives.

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, White House Office, Food & Drug Administration (FDA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MED

16. Specific lobbying issues

Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2024 Labor, Health and Human Services, Education and Related Agencies Appropriations bill .
Advocate for Defense Health Research Programs (CDMRP) in the FY24 Defense Appropriations Act, specifically the Melanoma Research Program (MRP) (H.R.4635).

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage.
Advocate for increased funding and reforms to Graduate Medical Education.
Advocate for improvements to Health Information Technology implementation.
Advocate for expansion of telemedicine services under Medicare and increased reimbursement for such services.
Advocate for improving disease management and care coordination for patients with chronic diseases.
Advocate for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS).
Advocate for relief from prior authorization requirements under Medicare Advantage and Medicare Part D plans.
Advocate for Congress to urge CMS to strengthen Qualified Clinical Data Registries (QCDRs) by removing barriers that restrict access to data from EHRs.
Advocate for congressional action to hold health care professionals harmless from any cuts related to CMS Evaluation and Management Code proposals in any forthcoming legislative package.
Advocate to replace scheduled and anticipated cuts in Medicare payments with positive, inflationary-based updates, eliminate the anticipated conversion factor cut in the CMS proposed rule for the 2024 Medicare Physician Fee Schedule (MPFS) associated with budget neutrality adjustments tied to Evaluation & Management (E/M) Code MPFS policy changes.
Support H.R.2474, Strengthening Medicare for Patients and Providers Act.
Support H.R. 3674, the Providing Relief and Stability for Medicare Patients Act of 2023.
Support the Resident Physician Shortage Reduction Act (S. 1302/H.R. 2389).
Advocate regarding matters related to Merit-based Incentive Payment System (MIPS), MIPS Value Pathways (MVPs), and Qualified Clinical Data Registries.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

Oppose the Tanning Tax Repeal Act (H.R. 936)

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code PHA

16. Specific lobbying issues

Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.
Advocate for a stable supply of medications and mitigate drug shortages.
Advocate for increased transparency regarding drug pricing.
Advocate for reducing barriers to entry of generic drugs into the marketplace.
Advocate for transparency on the part of pharmaceutical benefit managers.
Advocate for patient access to compounded medications.
Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals.
Advocate for implementation of language to direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes (enacted as part of P.L. 117-328, Consolidated Appropriations Act, 2023, H.R. 2617).
Support S. 127, Pharmacy Benefit Manager Transparency Act
Support H.R. 830/ S. 1375, the Help Ensure Lower Patient (HELP) Copays Act.
Support S. 935, the Fair Accountability & Innovative Research (FAIR) Drug Pricing Act

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2024 Labor, Health and Human Services, Education and Related Agencies Appropriations bill.
Advocate for adequate funding for the Agency for Healthcare Research and Quality (AHRQ) via the FY2024 Labor, Health and Human Services, Education and Related Agencies Appropriations bill.
Advocate for the FDA to implement the 2015 rule, General and Plastic Surgery Devices: Restricted Sale, Distribution, and Use of Sunlamp Products; and the Sunlamp Products Proposed; Amendment to Performance Standard, which would ban minors under the age of 18 from using tanning beds.
Advocate to replace scheduled and anticipated cuts in Medicare payments with positive, inflationary-based updates, eliminate the anticipated conversion factor cut in the CMS proposed rule for the 2024 Medicare Physician Fee Schedule (MPFS) associated with budget neutrality adjustments tied to Evaluation & Management (E/M) Code MPFS policy changes.
Advocate for increased funding for the Indian Health Services via the FY 2024 Interior-Environment Appropriations bill
Advocate for Defense Health Research Programs (CDMRP) in the FY24 Defense Appropriations Act, specifically the Melanoma Research Program (MRP) (H.R. 4365)
Advocate for report language studying veterans access to dermatologic care and preventative measures via the FY2024 Veterans Affairs-Military-Construction Appropriations bill (H.R. 4366/S.2127)

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different than line 20)

22. New General description of client’s business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities:

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
No Yes